delandistrogene moxeparvovec
AXP000254.1 · Viral vector gene therapy
- Platform
- AAVrh74 vector
- Targets
- DMD
- Originator
- Nationwide Children's Hospital
- Sponsor
- Sarepta Therapeutics
Names
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus rh74
- Strain
- AAVrh74
- Replication
- non replicating
- Modifications
- MHCK7 (myosin heavy chain kinase 7) promoter
- Transgenes
- micro-dystrophin (DMD)
- Route
- intravenous
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2023-06-22 | conditional | Elevidys | Accelerated approval: ambulatory paediatric patients aged 4 through 5 with a confirmed DMD mutation; extended to patients 4 and older by a 2024-06-20 supplement | source |
| PMDA | JP | 2025-05-13 | conditional | Elevidys | Duchenne muscular dystrophy in ambulatory patients aged 3 to under 8 years who are negative for anti-AAVrh74 antibodies; conditional and time-limited approval, for three years | source |
Clinical trials (11)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07542314 | Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting | Recruiting | Phase 4 | 2026-11-30 | 2027-08-31 | 20 | Duchenne Muscular Dystrophy |
| NCT06597656 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 | Terminated | Phase 1 | 2024-09-18 | 2025-08-05 | 3 | Duchenne Muscular Dystrophy |
| NCT06270719 | An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy | Enrolling by invitation | 2024-02-07 | 2028-12-31 | 500 | Duchenne Muscular Dystrophy | |
| NCT06241950 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) | Terminated | Phase 1 | 2024-01-29 | 2025-10-10 | 5 | Duchenne Muscular Dystrophy |
| NCT06128564 | A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) | Active not recruiting | Phase 2 | 2023-11-29 | 2026-03-04 | 13 | Duchenne Muscular Dystrophy |
| NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study | Enrolling by invitation | Phase 3 | 2023-09-27 | 2033-10-31 | 400 | Duchenne Muscular Dystrophy |
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | Active not recruiting | Phase 3 | 2023-05-31 | 2027-05-31 | 148 | Duchenne Muscular Dystrophy |
| NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | Completed | Phase 3 | 2021-10-27 | 2023-10-04 | 126 | Duchenne Muscular Dystrophy |
| NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | Recruiting | Phase 1 | 2020-11-23 | 2027-12-31 | 83 | Duchenne Muscular Dystrophy |
| NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) | Completed | Phase 1/2 | 2018-12-05 | 2020-12-08 | 41 | Muscular Dystrophy, Duchenne |
| NCT03375164 | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | Completed | Phase 1/2 | 2018-01-04 | 2023-04-25 | 4 | Duchenne Muscular Dystrophy |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41182527 | Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial. | Neurology and therapy | 2026 | cited by trial NCT05096221 |
| PMID 41518520 | Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. | Neurology and therapy | 2026 | cited by trial NCT05096221 |
| PMID 41672410 | ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy. | Pediatrics | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 41681118 | Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management. | Human gene therapy | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 41854298 | Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy. | Journal of neuromuscular diseases | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 42237476 | Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study. | Muscle & nerve | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 42944976 | Three-Year Follow-Up of Delandistrogene Moxeparvovec in Duchenne Muscular Dystrophy: Long-Term Phase 3 EMBARK Trial Results. | Neurology and therapy | 2026 | cited by trial NCT05096221 |
| PMID 39385046 | AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. | Nature medicine | 2025 | cited by trial NCT05096221 |
| PMID 39589719 | Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy. | Neurology and therapy | 2025 | cited by trial NCT05096221 |
| PMID 39747998 | Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. | Scientific reports | 2025 | cited by trial NCT04626674 |
| PMID 40354061 | Quantitative Muscle Magnetic Resonance Outcomes in Patients With Duchenne Muscular Dystrophy: An Exploratory Analysis From the EMBARK Randomized Clinical Trial. | JAMA neurology | 2025 | cited by trial NCT05096221 |
| PMID 41037163 | Dystrophinopathies. | Continuum (Minneapolis, Minn.) | 2025 | name in abstract: delandistrogene moxeparvovec |
| PMID 37577753 | Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. | Muscle & nerve | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 38753764 | Validity of remote live stream video evaluation of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. | PloS one | 2024 | cited by trial NCT03375164 |
| PMID 37539981 | Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR). | Annals of neurology | 2023 | cited by trial NCT03375164 |
| PMID 32539076 | Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. | JAMA neurology | 2020 | cited by trial NCT03375164 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41047627 | Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns. | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 41248852 | Drug-induced liver injury: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database (2004-2024). | Annals of hepatology | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 41310179 | Real-world experience with gene therapy in Duchenne muscular dystrophy center readiness and patients safety: report from Qatar. | Gene therapy | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 41422802 | Safety and efficacy of commercially administered elevidys (delandistrogene moxeparvovec-rokl). | Molecular therapy : the journal of the American Society of Gene Therapy | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 41919975 | Treatment advances for Duchenne muscular dystrophy. | Current opinion in pediatrics | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 41944036 | Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis. | Circulation. Heart failure | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 42031513 | Delandistrogene moxeparvovec: gene therapy for Duchenne muscular dystrophy. | Archives of disease in childhood. Education and practice edition | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 42384320 | Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up. | Cardiology and therapy | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 42396397 | Duchenne Muscular Dystrophy and Delandistrogene Moxeparvovec Gene Therapy in Children: A Systematic Review and Meta-Analysis. | Neurology. Genetics | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 42510866 | Recalibrating Therapeutic Priorities for Duchenne Muscular Dystrophy: A Critical Synthesis of Approved and Emerging Strategies Through the Lens of an Underrepresented Population. | Genes | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 42552850 | Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy. | Human gene therapy | 2026 | name in title: delandistrogene moxeparvovec |
| PMID 42668237 | 289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands. | Neuromuscular disorders : NMD | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 42841104 | Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy. | Frontiers in molecular medicine | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 42998121 | Public Participation in U.S. Food and Drug Administration (FDA) Advisory Committees: A Qualitative Analysis. | Therapeutic innovation & regulatory science | 2026 | name in abstract: delandistrogene moxeparvovec |
| PMID 39615430 | Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Requiring Intravenous Immunoglobulin. | Pediatric neurology | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 39720847 | Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect? | Expert opinion on drug safety | 2025 | name in abstract: delandistrogene moxeparvovec |
| PMID 39899275 | The latest developments in synthetic approaches to Duchenne muscular dystrophy. | Expert review of neurotherapeutics | 2025 | name in abstract: delandistrogene moxeparvovec |
| PMID 40367405 | Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee. | Neurology | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 40495560 | Some functional improvements in placebo and Delandistrogene moxeparvovec-treated trial participants explained by increased corticosteroid dosing. | Journal of neuromuscular diseases | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 40569438 | Efficacy of delandistrogene moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis. | Human genetics | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 40737572 | Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in Focus: Report of the AAN Guidelines Subcommittee. | Neurology | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 40763125 | FDA Investigating Sarepta's Elevidys® after Second Patient Dies. | Human gene therapy | 2025 | name in title: Elevidys |
| PMID 40817386 | AAV microdystrophin gene replacement therapy for Duchenne muscular dystrophy: progress and prospects. | Gene therapy | 2025 | name in abstract: Elevidys |
| PMID 40848523 | Gene therapy for Duchenne muscular dystrophy. | Brain & development | 2025 | name in abstract: delandistrogene moxeparvovec |
| PMID 40868246 | Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives. | Biomedicines | 2025 | name in abstract: Elevidys |
| PMID 40985181 | Anaphylaxis During Delandistrogene Moxeparvovec Infusion Therapy in a Boy With Duchenne Muscular Dystrophy. | Muscle & nerve | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 41061325 | Reversal of Acute Liver Injury Following Delandistrogene Moxeparvovec Gene Therapy Using Sirolimus and Immunoglobulin. | Pediatric neurology | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 41391912 | Gene therapy in Duchenne muscular dystrophy. | Archives de pediatrie : organe officiel de la Societe francaise de pediatrie | 2025 | name in abstract: delandistrogene moxeparvovec |
| PMID 41403450 | Delandistrogene Moxeparvovec gene therapy for Duchenne muscular dystrophy: the way forward in South Asian countries. | The Lancet regional health. Southeast Asia | 2025 | name in title: delandistrogene moxeparvovec |
| PMID 38291016 | Duchenne muscular dystrophy: promising early-stage clinical trials to watch. | Expert opinion on investigational drugs | 2024 | name in abstract: Elevidys |
| PMID 38306745 | Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular Dystrophy. | Pediatric neurology | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 38327805 | Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74. | Molecular therapy. Methods & clinical development | 2024 | name in abstract: delandistrogene moxeparvovec |
| PMID 38607761 | Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. | Journal of neuromuscular diseases | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 38748280 | [How safe is gene therapy? : Second death after Duchenne therapy]. | Innere Medizin (Heidelberg, Germany) | 2024 | name in abstract: delandistrogene moxeparvovec |
| PMID 39098058 | Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion. | Pediatric neurology | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 39137177 | In brief: Expanded indication for Elevidys. | The Medical letter on drugs and therapeutics | 2024 | name in title: Elevidys |
| PMID 39152743 | The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process. | Expert opinion on biological therapy | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 39447441 | Response to Hamid et al., "Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy". | Pediatric neurology | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 39593150 | Neuromuscular diseases: genomics-driven advances. | Genomics & informatics | 2024 | name in abstract: delandistrogene moxeparvovec |
| PMID 39607794 | Long-Term Survival and Myocardial Function Following Systemic Delivery of Delandistrogene Moxeparvovec in DMDMDX Rats. | Human gene therapy | 2024 | name in title: delandistrogene moxeparvovec |
| PMID 37261034 | Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. | Journal of market access & health policy | 2023 | name in title: delandistrogene moxeparvovec |
| PMID 37497476 | Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. | Frontiers in cell and developmental biology | 2023 | name in title: delandistrogene moxeparvovec |
| PMID 37566211 | Delandistrogene Moxeparvovec: First Approval. | Drugs | 2023 | name in title: delandistrogene moxeparvovec |
| PMID 37674905 | Paving the way for future gene therapies: A case study of scientific spillover from delandistrogene moxeparvovec. | Molecular therapy. Methods & clinical development | 2023 | name in title: delandistrogene moxeparvovec |
| PMID 37755693 | Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy. | The Medical letter on drugs and therapeutics | 2023 | name in title: delandistrogene moxeparvovec |
| PMID 38046199 | Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy. | Molecular therapy. Methods & clinical development | 2023 | name in abstract: Elevidys |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01AR040864 | Dystrophin Replacement | UNIVERSITY OF WASHINGTON | CHAMBERLAIN, JEFFREY S | 2026–2026 | name in abstract: Elevidys |
| R01AR085068 | MR Assessment of the effect of nNOS on Bioenergetics and Microvascular Function in Becker and Duchenne Muscular Dystrophy | UNIVERSITY OF FLORIDA | FORBES, SEAN C | 2025–2026 | name in abstract: Elevidys |
| R56NS147542 | Treg-mediated tolerance of dystrophin immunity | UNIVERSITY OF CALIFORNIA-IRVINE | VILLALTA, SERGIO ARMANDO | 2026–2026 | name in abstract: Elevidys |
Notes
AAVrh74 vector with the MHCK7 promoter delivering a micro-dystrophin transgene for Duchenne muscular dystrophy. Accelerated approval 2023-06-22 for ambulatory patients aged 4-5; a 2024-06-20 supplement extended it to patients 4 and older. Development code SRP-9001.
How to cite
delandistrogene moxeparvovec (AXP000254.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000254.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.